Float Short %

9.83

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

-0.14

EPS Last/This Y

EPS This/Next Y

0.08

Price

19.94

Target Price

24.8

Analyst Recom

1.95

Performance Q

17.15

Relative Volume

0.8

Beta

0.44

Ticker: ACAD

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	ACAD	19.11	0.33	0.02	14093
2025-01-24	ACAD	18.68	0.30	0.41	15185
2025-01-27	ACAD	18.28	0.31	0.58	15229
2025-01-28	ACAD	18.45	0.32	0.76	15625
2025-01-29	ACAD	18.38	0.32	0.59	15783
2025-01-30	ACAD	18.67	0.32	0.09	15791
2025-01-31	ACAD	18.66	0.32	0.00	15803
2025-02-03	ACAD	18.44	0.32	0.31	15801
2025-02-04	ACAD	18.74	0.32	0.09	15800
2025-02-05	ACAD	19.59	0.32	0.64	16007
2025-02-06	ACAD	19.14	0.33	0.30	16261
2025-02-07	ACAD	18.56	0.36	0.12	16638
2025-02-10	ACAD	18.89	0.36	0.00	16671
2025-02-11	ACAD	18.49	0.36	0.00	16684
2025-02-12	ACAD	19.09	0.36	0.00	16690
2025-02-13	ACAD	19.77	0.20	0.10	26791
2025-02-14	ACAD	20.05	0.20	0.00	27329
2025-02-18	ACAD	19.75	0.20	0.09	27489
2025-02-19	ACAD	19.68	0.20	0.04	27526
2025-02-20	ACAD	20.29	0.20	0.08	27588
2025-02-21	ACAD	19.94	0.20	0.03	27800
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	ACAD	19.08	-24.1	65.5	0.69
2025-01-24	ACAD	18.68	-24.1	47.3	0.69
2025-01-27	ACAD	18.27	-24.1	47.2	0.69
2025-01-28	ACAD	18.42	-24.1	53.0	0.69
2025-01-29	ACAD	18.36	-23.8	51.0	0.69
2025-01-30	ACAD	18.69	-23.8	54.8	0.69
2025-01-31	ACAD	18.66	-23.3	51.1	0.69
2025-02-03	ACAD	18.51	-23.6	49.8	0.69
2025-02-04	ACAD	18.74	-23.6	53.8	0.69
2025-02-05	ACAD	19.59	-23.6	60.4	0.69
2025-02-06	ACAD	19.14	-23.6	46.8	0.69
2025-02-07	ACAD	18.55	-23.6	45.5	0.69
2025-02-10	ACAD	18.88	-23.6	54.9	0.69
2025-02-11	ACAD	18.49	-23.6	47.4	0.69
2025-02-12	ACAD	19.09	-23.6	57.8	0.69
2025-02-13	ACAD	19.76	-23.6	58.2	0.69
2025-02-14	ACAD	20.04	-23.6	54.0	0.69
2025-02-18	ACAD	19.75	-21.8	48.6	0.69
2025-02-19	ACAD	19.67	-21.8	50.7	0.69
2025-02-20	ACAD	20.30	-21.8	57.5	0.69
2025-02-21	ACAD	19.94	-21.8	48.1	0.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	ACAD	-3.48	-4.51	6.52
2025-01-24	ACAD	-3.48	-4.51	6.52
2025-01-27	ACAD	-3.48	-3.03	6.52
2025-01-28	ACAD	-3.48	-3.03	10.42
2025-01-29	ACAD	-3.48	-3.03	10.42
2025-01-30	ACAD	-3.48	-3.03	10.42
2025-01-31	ACAD	-3.48	-3.03	10.42
2025-02-03	ACAD	-3.48	-3.29	10.42
2025-02-04	ACAD	-3.48	-3.29	10.42
2025-02-05	ACAD	-3.48	-3.29	10.42
2025-02-06	ACAD	-3.48	-3.29	10.42
2025-02-07	ACAD	-3.48	-3.29	10.42
2025-02-10	ACAD	-3.48	-3.23	10.42
2025-02-11	ACAD	-3.43	-3.23	10.42
2025-02-12	ACAD	-3.43	-3.23	9.88
2025-02-13	ACAD	-3.48	-3.23	9.88
2025-02-14	ACAD	-3.48	-3.23	9.88
2025-02-18	ACAD	-3.48	4.06	9.88
2025-02-19	ACAD	-5.44	4.06	9.83
2025-02-20	ACAD	-5.44	4.06	9.83
2025-02-21	ACAD	-1.84	4.06	9.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.2

Avg. EPS Est. Current Quarter

0.21

Avg. EPS Est. Next Quarter

0.06

Insider Transactions

-1.84

Institutional Transactions

4.06

Beta

0.44

Average Sales Estimate Current Quarter

278

Average Sales Estimate Next Quarter

233

Fair Value

25.43

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-77.2

Target Price

24.8

P/E

25.83

Forward P/E

27.44

PEG

P/S

3.57

P/B

5.75

P/Free Cash Flow

16.38

EPS

0.77

Average EPS Est. Cur. Y

0.69

EPS Next Y. (Est.)

0.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.83

Relative Volume

0.8

Return on Equity vs Sector %

Return on Equity vs Industry %

18.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

48.1

ACADIA Pharmaceuticals Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 620

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

stock quote shares ACAD – ACADIA Pharmaceuticals Inc. Stock Price stock today

news today ACAD – ACADIA Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ACAD – ACADIA Pharmaceuticals Inc. yahoo finance google finance

stock history ACAD – ACADIA Pharmaceuticals Inc. invest stock market

stock prices ACAD premarket after hours

ticker ACAD fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ACAD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y